A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- Sponsor
- Sinocelltech Ltd.
- Study ID
- NCT06774664
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- SCTC21C — BIOLOGICALDrug: SCTC21C Administered SC
Study Details
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in subjects with plasma cell-driven autoimmune diseases
Key Dates
- Start date
- Jan 31, 2025
- Status verified
- Jan 2025
- Primary completion
- Sep 30, 2027
- Completion
- Mar 31, 2029
Study Design
- Enrollment
- 99 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Phase I: Dose-finding: Group 1Drug: SCTC21C Administered SC
- Experimental: Phase I: Dose-finding: Group 2Drug: SCTC21C Administered SC
- Experimental: Phase I: Dose-finding: Group 3Drug: SCTC21C Administered SC
- Experimental: Phase I: Dose-finding: Group 4Drug: SCTC21C Administered SC
- Experimental: Phase 2: Group 1Drug: SCTC21C Administered SC
- Experimental: Phase 2: Group 2Drug: SCTC21C Administered SC
- Placebo Comparator: Phase I: Dose-finding: Group 5Drug: SCTC21C Administered SC
- Placebo Comparator: Phase I: Dose-finding: Group 6Drug: SCTC21C Administered SC
- Placebo Comparator: Phase 1: Dose-finding: Group 7Drug: SCTC21C Administered SC
- Placebo Comparator: Phase 2: Group 3Drug: SCTC21C Administered SC
Primary Outcome Measure
Phase 1: Treatment-emergent adverse events (TEAEs), serious adverse events (SAEs). [ Time Frame: 36 Weeks ]
Central Contacts
- Qiang Zhou+86-10-58628288
Related Studies
- Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA NephropathyPHASE4 · Recruiting · Calliditas Therapeutics AB · Birmingham, Alabama
- Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney TissuePHASE2 · Recruiting · Otsuka Pharmaceutical Development & Commercialization, Inc. · Denver, Colorado
- Study of BHV-1400 in IgA NephropathyPHASE1 · Recruiting · Biohaven Therapeutics Ltd. · Farmington, Connecticut
- A Study of JADE101 in Participants With Immunoglobulin A NephropathyPHASE2 · Recruiting · Jade Biosciences, Inc. · Chula Vista, California